Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
This article was originally published in The Pink Sheet Daily
Executive Summary
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.
You may also be interested in...
Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.
Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.
Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
New data on Novartis' investigational oral multiple sclerosis therapy Gilenia (fingolimod) strengthened the efficacy profile of the low dose 0.5 mg version of the drug and highlighted potential benefits of switching from Biogen Idec's Avonex (interferon beta-1a)